| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/B978-0-12-397927-8.00005-1 |
| P698 | PubMed publication ID | 22959025 |
| P2093 | author name string | Michael A. Davies | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis | Q24310644 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells | Q24606438 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Genes that mediate breast cancer metastasis to the brain | Q24644008 | ||
| Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds | Q24650750 | ||
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition | Q27851405 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
| Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer | Q37974236 | ||
| New Target Therapies for Brain Metastases from Breast Cancer | Q37977974 | ||
| Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America | Q38376308 | ||
| Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. | Q38494311 | ||
| Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition | Q39428029 | ||
| RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models | Q39692674 | ||
| Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function | Q39692699 | ||
| B-RAF is a therapeutic target in melanoma | Q40543086 | ||
| Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis | Q40636438 | ||
| Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends | Q40704208 | ||
| Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. | Q41675125 | ||
| Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy | Q42848018 | ||
| Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer | Q43060951 | ||
| Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer | Q43184359 | ||
| Incidence of brain metastases in renal cell carcinoma treated with sorafenib | Q43256497 | ||
| Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma | Q43693202 | ||
| Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). | Q43846885 | ||
| Despite concerns, FDA panel backs EGFR inhibitor | Q44207650 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer | Q46116627 | ||
| Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib | Q46308015 | ||
| A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel | Q46448115 | ||
| The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity–United States, 2000 to 2006 | Q46525613 | ||
| A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma | Q47969082 | ||
| Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. | Q48145064 | ||
| The current causes of death in patients with malignant melanoma | Q48199362 | ||
| Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier | Q48341810 | ||
| Brain metastasis: opportunities in basic and translational research | Q48501358 | ||
| Frequent EGFR mutations in brain metastases of lung adenocarcinoma | Q48565410 | ||
| Activation of stat3 in human melanoma promotes brain metastasis | Q48616814 | ||
| Vemurafenib for Melanoma Metastases to the Brain | Q48763254 | ||
| Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases | Q49123747 | ||
| Update on the incidence and mortality from melanoma in the United States | Q50537865 | ||
| Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need | Q51869157 | ||
| Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. | Q54610975 | ||
| Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab | Q56777007 | ||
| Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors | Q58024790 | ||
| Breast Cancer | Q63090590 | ||
| Suppression of BRAF(V599E) in human melanoma abrogates transformation | Q79074168 | ||
| Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab | Q81151636 | ||
| Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy | Q81242220 | ||
| Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006 | Q82139808 | ||
| Melanoma | Q83742629 | ||
| A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases | Q84534632 | ||
| Prognostic factors for survival in melanoma patients with brain metastases | Q85226494 | ||
| KIT as a therapeutic target in metastatic melanoma | Q37701887 | ||
| Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics | Q37748089 | ||
| Potential approaches for drug delivery to the brain: past, present, and future | Q37764351 | ||
| Role of Intrathecal Rituximab and Trastuzumab in the Management of Leptomeningeal Carcinomatosis | Q37784351 | ||
| Therapy for metastatic melanoma: an overview and update | Q37873464 | ||
| Emerging insights into the molecular biology of brain metastases | Q37938489 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain | Q37968204 | ||
| Targeting Angiogenesis for Treatment of NSCLC Brain Metastases | Q37974234 | ||
| Major response to imatinib mesylate in KIT-mutated melanoma. | Q27851428 | ||
| Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors | Q27851431 | ||
| Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates | Q27851482 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling | Q27851628 | ||
| Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification | Q27851656 | ||
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis | Q27851671 | ||
| EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study | Q27851683 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors | Q28118852 | ||
| Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors | Q28272463 | ||
| Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants | Q28287782 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| Final version of 2009 AJCC melanoma staging and classification | Q29614803 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers | Q29615475 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Q29620648 | ||
| Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain | Q33283845 | ||
| Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study | Q33361043 | ||
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 | ||
| Sunitinib in metastatic renal cell carcinoma patients with brain metastases. | Q33391978 | ||
| Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT | Q33794917 | ||
| New strategies in melanoma: molecular testing in advanced disease | Q33943660 | ||
| Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial | Q34066501 | ||
| Non–Small Cell Lung Cancer | Q34129295 | ||
| High frequency of BRAF mutations in nevi | Q34160519 | ||
| Resistance to BRAF Inhibition in Melanomas | Q34166376 | ||
| Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma | Q34206554 | ||
| Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib | Q34393558 | ||
| High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update | Q34507305 | ||
| ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial | Q34522758 | ||
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 | ||
| Targeted therapy for melanoma: a primer | Q34540273 | ||
| Erlotinib in lung cancer - molecular and clinical predictors of outcome | Q34559274 | ||
| Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib | Q34566991 | ||
| Somatic activation of KIT in distinct subtypes of melanoma | Q34569987 | ||
| Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study | Q34614776 | ||
| Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy | Q34633703 | ||
| Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis | Q35409064 | ||
| Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians | Q35628121 | ||
| Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF | Q35700459 | ||
| Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy | Q35705221 | ||
| Management of cutaneous melanoma | Q35877006 | ||
| Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer | Q35914677 | ||
| HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors | Q36025680 | ||
| Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience | Q36136110 | ||
| Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment | Q36395200 | ||
| Where next for gefitinib in patients with lung cancer? | Q36496065 | ||
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 | ||
| Point mutations of protein kinases and individualised cancer therapy | Q36632245 | ||
| Brain metastases: the HER2 paradigm | Q36760996 | ||
| Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. | Q36882732 | ||
| Multidisciplinary management of brain metastases | Q36900730 | ||
| Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features | Q37036930 | ||
| A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | Q37054957 | ||
| Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens | Q37380452 | ||
| Diagnosis and treatment of melanoma brain metastasis: a literature review | Q37531863 | ||
| Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. | Q37681223 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | targeted therapy | Q492646 |
| P304 | page(s) | 109-142 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Advances in Pharmacology | Q15753809 |
| P1476 | title | Targeted therapy for brain metastases | |
| Targeted Therapy for Brain Metastases | |||
| P478 | volume | 65 |
| Q100416113 | LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy |
| Q89161805 | Profiles of brain metastases: Prioritization of therapeutic targets |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
Search more.